Selegiline (pharmacology) < Selegiline (therapeutic use) < Selegiline HCl

Facettes :

List of bibliographic references indexed by Selegiline (therapeutic use)

Number of relevant bibliographic references: 30.
[0-20] [0 - 20][0 - 30][20-29][20-40]

Ident.	Authors (with country if any)	Title
000922 (2013)	Radu Constantinescu [États-Unis] ; Jordan Elm [États-Unis] ; Peggy Auinger [États-Unis] ; Saloni Sharma [États-Unis] ; Erika F. Augustine [États-Unis] ; Laith Khadim [États-Unis] ; Karl Kieburtz [États-Unis]	Malignant Melanoma in Early-Treated Parkinson's Disease: The NET-PD Trial
002483 (2009)	Connie Marras [Canada] ; Anthony E. Lang [Canada] ; Shirley W. Eberly [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Steven R. Schwid [États-Unis] ; Christopher Hyson [Canada] ; Ira Shoulson [États-Unis]	A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts
002679 (2008)	Connie Marras [Canada] ; Michael P. Mcdermott [États-Unis] ; Paula A. Rochon [Canada] ; Caroline M. Tanner [États-Unis] ; Gary Naglie [Canada] ; Anthony E. Lang [Canada]	Predictors of deterioration in health‐related quality of life in Parkinson's disease: Results from the DATATOP trial
002D64 (2007)	Tua Annanmaki [Finlande] ; Antti Muuronen [Finlande] ; Kari Murros [Finlande]	Low plasma uric acid level in Parkinson's disease
003811 (2005)	Cheryl Waters [États-Unis]	Other pharmacological treatments for motor complications and dyskinesias
003924 (2005)	Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal]	Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
003A84 (2004)	Cheryl H. Waters [États-Unis] ; Kapil D. Sethi [États-Unis] ; Robert A. Hauser [États-Unis] ; Eric Molho [États-Unis] ; John M. Bertoni [États-Unis]	Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study
003E24 (2004)	Susan Hollán [Hongrie] ; Lászl Vécsei [Hongrie] ; Kálmán Magyar [Hongrie]	Adverse effects of dopamine potentiation by long‐term treatment with selegiline
003E31 (2004)	Carl E. Clarke [Royaume-Uni]	A “cure” for Parkinson's disease: Can neuroprotection be proven with current trial designs?
004250 (2002)	Manavdeep Grewal [Canada] ; Raed Hawa [Canada] ; Colin Shapiro [Canada]	Treatment of periodic limb movements in sleep with selegiline HCl
004346 (2002)	Christopher G. Goetz [États-Unis] ; Sue Leurgans [États-Unis] ; Rema Raman [États-Unis]	Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease
004396 (2002)		MAO‐B inhibitors for the treatment of Parkinson's disease
004933 (2000)	Robert A. Hauser [États-Unis] ; William C. Koller [États-Unis] ; Jean P. Hubble [États-Unis] ; Teresita Malapira [États-Unis] ; Karen Busenbark [États-Unis] ; C. Warren Olanow [États-Unis]	Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease
004D56 (1999)	Robert B. Innis ; Kenneth L. Marek ; Kim Sheff ; Sami Zoghbi ; Joseph Castronuovo [États-Unis] ; Andrew Feigin [États-Unis] ; John P. Seibyl	Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT
004F03 (1998)	Andreas Kupsch [Allemagne] ; Oertel [Allemagne]	Selegiline, pregnancy, and Parkinson's disease
004F04 (1998)	Korczyn [Israël] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Warner H. Poewe [Autriche] ; Olivier Rascol [France] ; Fabrizzio Stocchi [Italie]	Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study
005171 (1998)	C. W. Olanow [États-Unis] ; C. Mytilineou [États-Unis] ; W. Tatton [États-Unis]	Current status of selegiline as a neuroprotective agent in Parkinson's disease
005259 (1997)	Lyytinen [Finlande] ; Seppo Kaakkola [Finlande] ; Sirpa Ahtila [Finlande] ; P Ivi Tuomainen [Finlande] ; Heikki Ter V Inen [Finlande]	Simultaneous MAO‐B and COMT inhibition in L‐dopa‐treated patients with parkinson's disease
005265 (1997)	Hauser [États-Unis] ; Theresa A. Zesiewicz [États-Unis]	Sertraline for the treatment of depression in parkinson's disease
005359 (1997)	Irfan Soykan ; Irene Sarosiek [États-Unis] ; Jeannie Shifflett ; George F. Wooten [États-Unis] ; McCallum	Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with parkinson's disease
005428 (1997)	Nathalie Andreu [France] ; Christine Damase-Michel [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Montastruc [France]	A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Selegiline (therapeutic use)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Selegiline (therapeutic use)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Selegiline (therapeutic use)
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024